Compare PCVX & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | EHC |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.7B |
| IPO Year | 2020 | 1994 |
| Metric | PCVX | EHC |
|---|---|---|
| Price | $60.31 | $101.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $88.25 | ★ $143.29 |
| AVG Volume (30 Days) | ★ 1.1M | 833.7K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | N/A | ★ 24.22 |
| EPS | N/A | ★ 5.54 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.33 |
| Revenue Next Year | N/A | $8.14 |
| P/E Ratio | ★ N/A | $18.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.09 | $92.77 |
| 52 Week High | $65.00 | $127.99 |
| Indicator | PCVX | EHC |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 44.26 |
| Support Level | $52.04 | $94.47 |
| Resistance Level | $65.00 | $109.21 |
| Average True Range (ATR) | 2.16 | 2.47 |
| MACD | -0.08 | -0.26 |
| Stochastic Oscillator | 51.54 | 7.85 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.